RxDoctor Payments DataLook up a doctor →

Paul Gerczuk, MD

Clinical Cardiac Electrophysiology · Tampa, FLNPI 1619291994

Payments from drug & device makers

$288,228in general payments, 2019–2025

Across 1,997 payments — averaging $144.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$178K
  • Boston Scientific$67K
  • Elutia, Inc.$24K
  • Medtronic$4K
  • Atricure, Inc.$3K
  • Abbott$3K
  • plus $9K from 39 others

What the payments were for

  • Consulting fees$9,40825%
  • Speaking & faculty fees$4,61412%
  • Travel & lodging$5,17214%
  • Food & beverage$18,96750%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$288,228 in reported general payments places this provider in the 85th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$777,724
Medicare patients
1,156
Services billed
5,605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban776$883,297
XareltoRivaroxaban293$344,572
EntrestoSacubitril/Valsartan86$111,511
MultaqDronedarone Hcl63$89,112
Repatha SureclickEvolocumab35$43,116
Dofetilide152$41,166
FarxigaDapagliflozin Propanediol32$30,494
Praluent PenAlirocumab12$14,814
Repatha SyringeEvolocumab17$12,552
Flecainide Acetate251$11,788
Propafenone Hcl ErPropafenone Hcl38$9,054
Amiodarone Hcl379$7,227
Bisoprolol Fumarate236$6,914
Dabigatran EtexilateDabigatran Etexilate Mesylate15$6,456
Diltiazem 24hr Er (Cd)Diltiazem Hcl197$5,840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$493$883,297776 claims
Johnson & JohnsonXarelto$171$344,572293 claims
NovartisEntresto$496$111,51186 claims
Sanofi-aventis U.S. LLCMultaq$576$89,11263 claims
AstraZenecaFarxiga$173$30,49432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →